drugset / Trial / NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Timeline
- Start
- 2024-08-30
- Primary completion
- 2030-07-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |